Help! Please Register
IQ Option http://iqoption.net.co/ en colombia
  Education &
  Tools

  Introduction
  Abbreviations
  Links
  CME
  Conference
   Highlights
  Bibliography
  Glossary
  Good Books
  Events Calendar


  Mycoses

  Introduction
  Human
  Veterinary
  Environmental
   Industrial
  Agricultural
  MSG


  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank


  Drugs

  Introduction
  Medical
  Veterinary
  Environmental
   Industrial
  Agricultural


  Laboratory

  Introduction
  Susceptibility
  MIC Database
  Procedures
  Histopathology


  About Us

  Introduction
  Our Mission
  Editorial Board
  Editorial Staff
  Supporters
  Contributors
  Legal Stuff
  Privacy Policy
  Kudos


  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank



This page updated:
1/27/2007 9:23:00 AM


DoctorFungus - All Rights Reserved © 2007 Copyright
& Privacy Policy


Site built and designed for doctorfungus by Webillustrated



You are here: Education & Tools >
Astellas Pharma Inc.

conference highlightsConference Highlights

Focus on Fungal Infections 13


Clinical Mycology
  1. SEROTYPES DISTRIBUTION AND DRUG SUSCEPTIBILITIES OF CRYPTOCOCCUS NEOFORMANS AND CANDIDA ALBICANS FROM CLINICAL SOURCES IN NAIROBI, KENYA
    Bii CC, Revathi G, Kenya Medical Research Institute,
    Nairobi, Kenya


  2. TRENDS OF CANDIDEMIA AMONG SURGICAL INTENSIVE CARE UNIT (SICU) PATIENTS
    Goff DA, The Ohio State University Medical Center,
    Columbus, United States


  3. SUPERFICIAL AND CUTANEOUS FUNGAL INFECTIONS IN RENAL TRANSPLANT PATIENTS OF GUATEMALA
    Pellecer D, Clinica Familiar, Hospital General San Juan de Dios,
    Guatemala City, Guatemala


  4. CRYPTOCOCCUS NEOFORMANS INFECTION IN SOLID ORGAN TRANSPLANT (SOT)
    Razonable RR, Patel R, Mayo Clinic,
    Rochester, United States


  5. PATHOGENICITY, HEAVY METAL AND OXIDATIVE STRESS SENSITIVITY OF CANDIDA ALBICANS MORPHOLOGICAL MUTANTS AND THEIR HYBRIDE
    Pesti M, Novak A, Emody L, Vagvolgyi C, University of Pecs,
    Pecs, Hungary


  6. FUNGAL TOENAIL INFECTIONS IN NEUTROPENIC PATIENTS
    Elko L, Greene J, Sandin R, Vincent A, University of South Florida,
    Miami, United States


  7. TOXINOGENICITY OF ASPERGILLUS FUMIGATUS AND A. VERSICOLOR STRAINS ISOLATED FROM PULMONARY ASPERGILLOMA
    Pepeljnjak S, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia,
    Slobodnjak Z, Thoracic Surgery Unit, University Chest Clinic, Jordanovac, Zagreb, Croatia,
    Pavloviæ M, Institute for Medical Research and Occupational Health, Zagreb, Croatia


  8. FUNGAL INFECTIONS AS AN IMPORTANT CAUSE OF SEVERE SEPSIS
    Gaber G, Ottawa Hospital, Ottawa, Canada,
    Opal SM, Brown University, Providence, United States,
    Larosa SP, Cleveland Clinic, Cleveland, United States,
    Maki DG, University of Wisconsin, Madison, United States


  9. A COMPARISON OF CLINICAL SYMPTOMS OF PNEUMOCYSTIS CARINII PNEUMONIA BETWEEN HIV AND NON-HIV PATIENTS
    Kasahara K, Takahashi K, Konishi M, Uno K, Yoshimoto E, Murakawa K, Maeda K, Mikasa K, Kimura H, Kita E, Nara Medical University,
    Kashihara-City, Japan


  10. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH A HISTORY OF PRIOR INVASIVE ASPERGILLOSIS: OUTCOMES AND RISKS FOR POST-TRANSPLANT INVASIVE ASPERGILLOSIS
    Fukuda T, Owens SM, Boeckh M, Guthrie KA, Mattson DK, Wald A, Corey L, Storb RF, Marr KA, Fred Hutchinson Cancer Research Center,
    Seattle, United States


  11. INVASIVE FUNGAL INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER NONMYELOABLATIVE CONDITIONING: RISKS AND OUTCOMES
    Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Martin PJ, Storb RF, Marr KA, Fred Hutchinson Cancer Research Center,
    Seattle, United States


  12. CLINICAL PREDICTIVE MODELING IN CHILDREN
    Benjamin D, DeLong E, Duke University Clinical Research, Durham, United States,
    Steinbach W, Cotten C, Duke University Pediatrics, Durham, United States,
    Walsh T, National Cancer Institute, Bethesda, MD, United States Durham, United States,
    Clark R, Pediatrix Medical Group, Inc.


  13. PHARMACOECONOMICS OF PROPHYLAXIS OF FUNGAL INFECTIONS IN PATIENTS UNDERGOING A HEMATOPOIETIC STEM CELL TRANSPLANT
    Prendergast MM, Tong KB, Fujisawa Healthcare, Inc.,
    Deerfield, United States


  14. FAILURE OF TREATMENT OF CRYPTOCOCCOSIS IN A NONHIV INFECTED PATIENT
    Nguyen HH, Avante CJ, Siddiqui J, King J, Cohen SH, University of California, Davis,
    Sacramento, United States


  15. IS THE STANDARD DOSE OF SULFAMETHOXAZOLE / TRIMETHOPRIM ADEQUATE IN PATIENTS WITH AIDS-RELATED PNEUMOCYSTIS CARINII PNEUMONIA?
    Konishi M, Yoshimoto E, Takahashi K, Uno K, Kasahara K, Murakawa K, Maeda K, Mikasa K, Nara Medical University,
    Nara, Japan


  16. COMPARATIVE NEPHROTOXICITY, ADVERSE EVENTS, AND CLINICAL OUTCOMES WITH LIPID-ASSOCIATED AMPHOTERICIN B PRODUCTS
    Couch K, Christiana Care Health System, Newark, United
    States, Chan S, Cincotta E, University of Maryland Medical Center, Baltimore, United States,
    Piper JP, Christiana Care Health System, Newark, United States,
    Forrest G, University of Maryland Medical Center, Baltimore, United States


  17. A MULTI-CENTER, RETROSPECTIVE COMPARISON OF THE NEPHROTOXIC EFFECTS OF AMPHOTERICIN B LIPID COMPLEX AND LIPOSOMAL AMPHOTERICIN B
    McKechnie M, Rotstein C, McTaggart B, Hamilton Health Sciences,
    Hamilton, Canada


  18. INCIDENCE AND CONSEQUENCES OF NEPHROTOXICITY IN HSCT TREATED WITH EMPIRIC AMPHOTERICIN, MICAFUNGIN OR NO ANTI-FUNGAL AGENT
    Drajer D, Frame D, Kemper M, Weinstein A, RUSH Medical Center,
    Chicago, United States


  19. IN VITRO AND IN VIVO HUMAN METABOLISM OF ALBACONAZOLE
    Nadal T, Carbo M, Izquierdo I, De La Cruz G, Bartroli J, Merlos M, R & D Center,
    Barcelona, Spain


  20. SAFETY AND PRELIMINARY PHARMACOKINETICS OF AN ORAL SOLUTION CONTAINING ALBACONAZOLE AFTER SINGLE AND MULTIPLE DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS
    De La Cruz G, Rigau D, Nadal T, Carbo M, Lurigados C, Bartroli J, Zguierdo I, R & D Center,
    Barcelona, Spain


top of page    




View other categories
Antifungal Agents | Antifungal Combinations | Basic Mycology | Case Reports
Clinical Mycology | Animal Models | Diagnostics | Miscellaneous | View All





  Home | Image Bank | Lecture Bank | Knowledgebase | Site Map | Contact Us |
The Fungi | Mycoses | Drugs |
Laboratory | Education & Tools | About Us

  bttm_banner_indv2_02[1].gif